On February 22, 2022 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, reported that Thijs Spoor, Chief Executive Officer of Viewpoint, will participate in a fireside chat at the B. Riley Radiation Oncology Investor Day today, February 22, 2022 at 1:30 PM ET (Press release, Viewpoint Molecular Targeting, FEB 22, 2022, https://viewpointmt.com/viewpoint-molecular-targeting-to-present-at-the-b-riley-radiation-oncology-investor-day/ [SID1234608817]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The B. Riley Securities Radiation Oncology Investor Day, being held virtually on Tuesday, February 22nd, is designed to provide insights into the current state and future direction of the radiation oncology field by bringing together innovative companies and independent experts. The event features fireside chats with key public and private companies working in the space as well as an expert KOL panel discussion. Topics are expected to range from understanding and overcoming supply chain and logistical challenges unique to radiopharmaceuticals, to the potential competitive and/or complementary roles of external beam and targeted radiotherapies.

To register and for more information about the event, please visit the event website.